This on-demand features an expert case discussion on the current landscape of gastric cancer, from patient selection to treatment management to maximize benefit. Join Dr. James M. Cleary, Associate Professor of Medicine at Harvard Medical School, and Kathleen Madden, Family Nuse Practitioner at the Melanoma Program at NYU Langone Perlmutter Cancer Center in New York, NY, to learn more.
PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.
James M. Cleary, MD, PhD: consultant/advisor/speaker: Blueprint, Incyte; researcher: Apexigen, Arcus, AstraZeneca, Bayer, Bristol-Myers Squibb, Esperas Pharma, GlaxoSmithKline, Merck, Merus, Servier.
Kathleen Madden, FNP, MSN, AOCNP, APHN, has no relevant financial relationships to disclose.
The proposed educational program is planned for and will be targeted to oncology NPs, PAs, and nurses who manage patients with gastric cancer.
Upon completion of this activity, participants should be able to:
- Conduct recommended molecular testing at diagnosis and later stages of gastric/GEJ cancer
- Implement evidence-based guideline and molecular-guided strategies for treatment of patients with gastric/GEJ cancer
- Apply recommended strategies to identify and manage AEs associated with newer therapies used in this setting
Joint Accreditation Statement
In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Nursing Continuing Professional Development: The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour, including 1 hour of pharmacology credit.
Physician Associate Continuing Medical Education
Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until December 10, 2024. PAs should only claim credit commensurate with the extent of their participation.
IPCE Credit Designation
This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change.
This continuing education activity aims to improve NP and PA knowledge and clinical competency in the management of patients with gastric cancer, including implementing guidelines, use of evidence-based strategies for treatment selection and sequencing, and the identification and management of AEs.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Provided by Partners for Advancing Clinical Education (PACE).
Supported by an educational grant from Merck Sharp & Dohme, LLC.
What Is the Current Standard for First-Line Treatment of Metastatic HER2-Negative G/GEJ Cancers?1.00 program credit
Yelena Janjigian, MD
Claudin18.2: An Emerging Biomarker and Its Significance as a Therapeutic Target in G/GEJ Cancers1.00 program credit
Samuel J. Klempner, MD
Roy F. Chemaly, MD, MPH